CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?

CytomX Therapeutics (CTMX) , a clinical-stage oncology company, is slated to report its fourth-quarter 2024 earnings results on March 6, after market close. The company leverages its proprietary PROBODY therapeutic platform to discover and develop safer, more effective therapies for the treatment of cancer.See the Zacks Earnings Calendar to stay ahead of market-making news.The Zacks Consensus Estimate for CTMX’s loss per share in the to-be-reported quarter is currently pegged at 20 cents. CytomX also recogn ...